---
title: "Shanghai OPM Biosciences Co., Ltd. (688293.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688293.SH.md"
symbol: "688293.SH"
name: "Shanghai OPM Biosciences Co., Ltd."
industry: "Biotechnology"
---

# Shanghai OPM Biosciences Co., Ltd. (688293.SH)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | CN Market |
| Website | [www.opmbiosciences.com](https://www.opmbiosciences.com) |

## Company Profile

Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, and VegaCHO media and feeds, as well as customized cell culture media development s...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-18T04:30:09.000Z

**Overall: B (0.38)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 22.84% |  |
| Net Profit YoY | 13.53% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 2.61 |  |
| Dividend Ratio | 0.71% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 6.84B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 352.90M |  |


**Multi Score**: B

#### Profit Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.06% | C |
| Profit Margin | 12.25% | B |
| Gross Margin | 52.82% | B |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 22.84% | A |
| Net Profit YoY | 13.53% | C |
| Total Assets YoY | 0.61% | C |
| Net Assets YoY | -0.04% | C |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 816.12% | B |
| OCF YoY | 22.84% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.16 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 7.59% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai OPM Biosciences Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.06%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "12.25%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "52.82%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "22.84%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "13.53%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.61%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.04%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "816.12%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "22.84%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.16",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "7.59%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BeOne Medicines (SH.688235) | C | A | B | C | A | B |
| 02 | Gan & Lee (SH.603087) | B | B | D | A | B | B |
| 03 | Sunshine Guojian Pharmaceutical (SH.688336) | A | B | D | B | C | B |
| 04 | Biocytogen (SH.688796) | A | A | C | D | B | B |
| 05 | BTBP (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 158.29 | 35/83 | 294.32 | 174.80 | 133.76 |
| PB | 2.61 | 36/83 | 3.06 | 2.79 | 2.23 |
| PS (TTM) | 19.40 | 64/83 | 19.71 | 17.04 | 15.62 |
| Dividend Yield | 0.71% | 27/83 | 1.13% | 0.83% | 0.75% |

## Institutional View

### Analyst Rating Distribution

> As of 2025-11-01T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 52.64 |

## References

- [Company Overview](https://longbridge.com/en/quote/688293.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688293.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688293.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.